|
⚲
|
| Keyboard |
| LB Pharmaceuticals Inc | |
|---|---|
| Ticker | LBRX |
| CIK # | 0001691082 |
| CUSIP | 50180M108 |
| Sector | Life Sciences - Pharmaceutical Preparations |
| Address | 575 Madison Avenue, New York, NY 10022 |
| Source | [EDGAR] |
| Reg D Offering (Form D) | Filed | Raised | Terms |
|---|---|---|---|
| LB Pharmaceuticals Inc | 2023-09-21 | 110.7 M | Exemption: 506(b) · Duration: One year or less · Commission: $2,465,000 · Finder's Fee: $735,000 · Revenue: Decline to Disclose |
| CIK | Filing | 2011 - 2026 |
|---|---|---|
| [0001691082] | 10-K | |
| [0001691082] | 10-Q | |
| [0001691082] | 3 | |
| [0001691082] | 4 | |
| [0001691082] | 8-K | |
| [0001691082] | D | |
| [0001691082] | SC 13G |
| Form 13D/13G Filer | Form 13D/13G Subject | Filed | % Owned |
|---|---|---|---|
| JPMorgan Chase & Co | LB Pharmaceuticals Inc | [2026-07-16] | 0.0 |
| Caligan Partners LP | LB Pharmaceuticals Inc | [2026-05-15] | 0.0 |
| BlackRock Inc | LB Pharmaceuticals Inc | [2026-01-21] | 0.0 |
| JPMorgan Chase & Co | LB Pharmaceuticals Inc | [2026-01-21] | 0.0 |
| Trails Edge Capital Partners LP | LB Pharmaceuticals Inc | [2025-12-31] | 0.0 |
| BlackRock Portfolio Management LLC | LB Pharmaceuticals Inc | [2025-10-17] | 0.0 |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Lenz Robert A
Stock Option (Right to Buy) · derivative
|
2026-03-06 | Grant | 20,000 | $0.00 | |
|
Kroin David +3
Pre-Funded Warrants (Right to Buy) · derivative
|
2026-02-06 | Buy | 378,444 | $21.17 | 8,011,659 |
|
Kroin David +3
Pre-Funded Warrants (Right to Buy) · derivative
|
2026-02-06 | Buy | 93,925 | $21.17 | 1,988,392 |
|
Pai Panandiker Kaya Kamlesh
Employee Stock Option (Right to Buy) · derivative
|
2025-12-10 | Grant | 195,000 | $0.00 | |
|
Common Stock
|
2025-09-12 | Buy | 666,666 | $15.00 | 9,999,990 |
|
Common Stock
|
2025-09-12 | Conversion | 411,681 | ||
|
Common Stock
|
2025-09-12 | Buy | 1,000,000 | $15.00 | 15,000,000 |
|
Common Stock
|
2025-09-12 | Conversion | 411,681 | ||
|
Common Stock
|
2025-09-12 | Buy | 1,000,000 | $15.00 | 15,000,000 |
|
Common Stock
|
2025-09-12 | Buy | 332,566 | $15.00 | 4,988,490 |
|
Series C Preferred Stock · derivative
|
2025-09-12 | Conversion | 16,666,667 | ||
|
Series C Preferred Stock · derivative
|
2025-09-12 | Conversion | 10,000,000 | ||
|
Series C Preferred Stock · derivative
|
2025-09-12 | Conversion | 10,000,000 | ||
|
Series C Preferred Stock · derivative
|
2025-09-12 | Conversion | 30,667 | $0.00 | |
|
Series C Preferred Stock · derivative
|
2025-09-12 | Conversion | 13,302,666 | $0.00 | |
|
Common Stock
|
2025-09-12 | Buy | 767 | $15.00 | 11,505 |
|
Common Stock
|
2025-09-12 | Conversion | 547,648 | ||
|
Common Stock
|
2025-09-12 | Conversion | 1,262 | ||
|
Common Stock
|
2025-09-12 | Buy | 2,000,000 | $15.00 | 30,000,000 |
|
Common Stock
|
2025-09-12 | Conversion | 686,138 | ||
| showing 20 of 74 most recent transactions | |||||
| 13F Ownership Over Time | Holders | Shares Held |
|---|---|---|
| 2026-03-31 | 77 | 28,259,904 |
| 2025-12-31 | 68 | 24,789,575 |
| 2025-09-30 | 53 | 20,919,700 |
| Form 13F Holdings | ||||
|---|---|---|---|---|
| Firm | Period | DFND | Voting | Shares |
| Y-Intercept Hong Kong Ltd | [2026-06-30] | SOLE | 39,413 | 39,413 |
| Gamma Investing LLC | [2026-06-30] | DFND | 196 | 196 |
| MassMutual Private Wealth & Trust FSB | [2026-06-30] | SOLE | 54 | 54 | Prev | Page 1 | Next |